Search

Your search keyword '"Wagener, Nina"' showing total 170 results
Start Over Author "Wagener, Nina"
170 results on '"Wagener, Nina"'

4. Supplementary Data from Prognostic Value of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer

Author

Macher-Goeppinger, Stephan, primary, Aulmann, Sebastian, primary, Tagscherer, Katrin E., primary, Wagener, Nina, primary, Haferkamp, Axel, primary, Penzel, Roland, primary, Brauckhoff, Antje, primary, Hohenfellner, Markus, primary, Sykora, Jaromir, primary, Walczak, Henning, primary, Teh, Bin T., primary, Autschbach, Frank, primary, Herpel, Esther, primary, Schirmacher, Peter, primary, and Roth, Wilfried, primary

Published
2023
Full Text
View/download PDF

12. Welchen Einfluss hat die Dauer der Oberarzttätigkeit auf die Berufsausübung und Zufriedenheit urologischer OberärztInnen in Deutschland?

Author

Necknig, Ulrike H., additional, Wolff, Ingmar, additional, Bründl, Johannes, additional, Kriegmair, Maximilian C., additional, Marghawal, David, additional, Wagener, Nina, additional, Hegemann, Miriam, additional, Eder, Elisabeth, additional, Wülfing, Christian, additional, Burger, Maximilian, additional, Leyh, Herbert, additional, May, Matthias, additional, Kiesewetter, Jan, additional, and Weidenbusch, Marc, additional

Published
2020
Full Text
View/download PDF

13. Perioperative Blood Transfusion Is a Predictor of Acute and Chronic Renal Function Deterioration after Partial and Radical Nephrectomy for Renal Cell Carcinoma

Author

Mühlbauer, Julia, primary, de Gilde, Johannes, additional, Mueller-Steinhardt, Michael, additional, Porubsky, Stefan, additional, Walach, Margarete, additional, Nuhn, Philipp, additional, Klüter, Harald, additional, Wagener, Nina, additional, and Kriegmair, Maximilian C., additional

Published
2020
Full Text
View/download PDF

22. Externe Validierung und Decision-Curve-Analyse eines postoperativen Nomogramms zur Vorhersage des krankheitsfreien Überlebens von Patienten mit papillärem Nierenzellkarzinom anhand einer umfassenden multizentrischen internationalen Datenbank (CORONA - Collaborative Research on Renal Neoplasms Association - papRCC Projekt)

Author

Krabbe, Laura-Maria, Zastrow, Stefan, Wagener, Nina, Wolff, Ingmar, Borgmann, Hendrik, Huck, Nina, Shariat, Shahrokh, Ecke, Thorsten, Klatte, Tobias, Huetterer, Georg, May, Matthias, and Brookman-May, Sabine

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Anhand einer umfassenden multizentrischen internationalen Datenbank von Patienten mit papillärem Nierenzellkarzinom (papRCC) erfolgte die erstmalige Validierung eines publizierten postoperativen Nomograms zur Vorhersage des krankheitsfreien Überlebens von papRCC-Patienten. Methode:[zum vollständigen Text gelangen Sie über die oben angegebene URL], 65. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie

Published
2019

25. Adherens junctions of the human detrusor

Author

WAGENER, NINA, REITZ, ANDŔ, PFITZENMAIER, JESCO, PANNEK, JÜRGEN, BASTIAN, PATRICK J., BÜTTNER, REINHARD, MÜLLER, STEFAN C., HOHENFELLNER, MARKUS, and HAFERKAMP, AXEL

Published
2005

26. Operative Ergebnisse der partiellen Nephrektomie: Tumor oder Patient - Worauf kommt es an?

Author

Wunderle, Michael, Pfalzgraf, Daniel, Porubsky, Stefan, Wagener, Nina, and Kriegmair, Maximilian C.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Die partielle Nephrektomie (PN) gilt als Therapie der Wahl des organbegrenzten Nierenzellkarzinoms. Das organerhaltende Verfahren birgt das Risiko für eine relevante Rate an postoperativen Komplikationen und der Notwendigkeit der stationären Wiederaufnahme. Zur Abschätzung[zum vollständigen Text gelangen Sie über die oben angegebene URL], 59. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V. - Urologie im Südwesten: Innovation aus Tradition

Published
2018

27. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

Author

Pfitzenmaier Jesco, Schirmacher Peter, Hoppe-Seyler Karin, Hüsing Johannes, Pritsch Maria, Macher-Goeppinger Stephan, Wagener Nina, Haferkamp Axel, Hoppe-Seyler Felix, and Hohenfellner Markus

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The enhancer of zeste homolog 2 (EZH2) gene exerts oncogene-like activities and its (over)expression has been linked to several human malignancies. Here, we studied a possible association between EZH2 expression and prognosis in patients with renal cell carcinoma (RCC). Methods EZH2 protein expression in RCC specimens was analyzed by immunohistochemistry using a tissue microarray (TMA) containing RCC tumor tissue and corresponding normal tissue samples of 520 patients. For immunohistochemical assessment of EZH2 expression, nuclear staining quantity was evaluated using a semiquantitative score. The effect of EZH2 expression on cancer specific survival (CSS) was assessed by univariate and multivariate Cox regression analyses. Results During follow-up, 147 patients (28%) had died of their disease, median follow-up of patients still alive was 6.0 years (range 0-16.1 years). EZH2 nuclear staining was present in tumor cores of 411 (79%) patients. A multivariate Cox regression analysis revealed that high nuclear EZH2 expression was an independent predictor of poor CSS (> 25-50% vs. 0%: HR 2.72, p = 0.025) in patients suffering from non-metastatic RCC. Apart from high nuclear EZH2 expression, tumor stage and Fuhrman's grading emerged as significant prognostic markers. In metastatic disease, nuclear EZH2 expression and histopathological subtype were independent predictive parameters of poor CSS (EZH2: 1-5%: HR 2.63, p = 0.043, >5-25%: HR 3.35, p = 0.013, >25%-50%: HR 4.92, p = 0.003, all compared to 0%: HR 0.36, p = 0.025, respectively). Conclusions This study defines EZH2 as a powerful independent unfavourable prognostic marker of CSS in patients with metastatic and non-metastatic RCC.

Published
2010
Full Text
View/download PDF

28. Are there limits of robotic partial nephrectomy? TRIFECTA outcomes of open and robotic partial nephrectomy for completely endophytic renal tumors

Author

Harke, Nina N., primary, Mandel, Philipp, additional, Witt, Jorn H., additional, Wagner, Christian, additional, Panic, Andrej, additional, Boy, Anselm, additional, Roosen, Alexander, additional, Ubrig, Burkhard, additional, Schneller, Andreas, additional, Schiefelbein, Frank, additional, Wagener, Nina, additional, Honeck, Patrick, additional, Schoen, Georg, additional, Hadaschik, Boris, additional, Michel, Maurice S., additional, and Kriegmair, Maximilian C., additional

Published
2018
Full Text
View/download PDF

29. Organ Preservation Is Less Frequently Performed in Women Surgically Treated for Papillary Renal Cell Carcinoma—Results of a Comprehensive Multicenter Study

Author

Wolff, Ingmar, primary, Scavuzzo, Anna, additional, Capitanio, Umberto, additional, Klatte, Tobias, additional, Shariat, Shahrokh F., additional, Wagener, Nina, additional, Zastrow, Stefan, additional, Borgmann, Hendrik, additional, Krabbe, Laura-Maria, additional, Hutterer, Georg, additional, May, Matthias, additional, Brookman-May, Sabine D., additional, Cindolo, Luca, additional, Ecke, Thorsten, additional, Haferkamp, Axel, additional, Herrmann, Edwin, additional, Hohenfellner, Markus, additional, Hora, Milan, additional, Hoschke, Bernd, additional, Huck, Nina, additional, Rios, Miguel Angel Jimenez, additional, Mirvald, Cristian, additional, Musquera, Mireia, additional, Dell'Oglio, Paolo, additional, Pahernik, Sascha, additional, Prochazkova, Krystina, additional, Reynoso-Noverón, Nancy, additional, Stief, Christian G., additional, Surcel, Cristian, additional, Vergho, Daniel, additional, Waidelich, Raphaela, additional, Wirth, Manfred, additional, and Zigeuner, Richard, additional

Published
2017
Full Text
View/download PDF

32. Decoy Receptor 3 Is a Prognostic Factor in Renal Cell Cancer12

Author

Macher-Goeppinger, Stephan, Aulmann, Sebastian, Wagener, Nina, Funke, Benjamin, Tagscherer, Katrin E, Haferkamp, Axel, Hohenfellner, Markus, Kim, Sunghee, Autschbach, Frank, Schirmacher, Peter, and Roth, Wilfried

Subjects
Adult, Aged, 80 and over, Male, Receptors, Tumor Necrosis Factor, Member 6b, Middle Aged, Prognosis, Kidney Neoplasms, Cohort Studies, Tissue Array Analysis, Biomarkers, Tumor, Humans, Female, Carcinoma, Renal Cell, In Situ Hybridization, Fluorescence, Research Article, Aged
Abstract

Decoy receptor 3 (DcR3) is a soluble protein that binds to and inactivates the death ligand CD95L. Here, we studied a possible association between DcR3 expression and prognosis in patients with renal cell carcinomas (RCCs).A tissue microarray containing RCC tumor tissue samples and corresponding normal tissue samples was generated. Decoy receptor 3 expression in tumors of 560 patients was examined by immunohistochemistry. The effect of DcR3 expression on disease-specific survival and progression-free survival was assessed using univariate analysis and multivariate Cox regression analysis. Decoy receptor 3 serum levels were determined by ELISA.High DcR3 expression was associated with high-grade (P = .005) and high-stage (P = .048) RCCs. The incidence of distant metastasis (P = .03) and lymph node metastasis (P = .002) was significantly higher in the group with high DcR3 expression. Decoy receptor 3 expression correlated negatively with disease-specific survival (P.001) and progression-free survival (P.001) in univariate analyses. A multivariate Cox regression analysis retained DcR3 expression as an independent prognostic factor that outperformed the Karnofsky performance status. In patients with high-stage RCCs expressing DcR3, the 2-year survival probability was 25%, whereas in patients with DcR3-negative tumors, the survival probability was 65% (P.001). Moreover, DcR3 serum levels were significantly higher in patients with high-stage localized disease (P = .007) and metastatic disease (P = .001).DcR3 expression is an independent prognostic factor of RCC progression and mortality. Therefore, the assessment of DcR3 expression levels offers valuable prognostic information that could be used to select patients for adjuvant therapy studies.

Published
2008

33. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.

Author

Wagener, Nina, Edelmann, Dominic, Benner, Axel, Zigeuner, Richard, Borgmann, Hendrik, Wolff, Ingmar, Krabbe, Laura M., Musquera, Mireia, Dell’Oglio, Paolo, Capitanio, Umberto, Klatte, Tobias, Cindolo, Luca, May, Matthias, Brookman-May, Sabine D., and null, null

Subjects
*RENAL cell carcinoma, *PAPILLARY carcinoma, *MEDICAL databases, *RETROSPECTIVE studies, *COMPARATIVE studies, *PROGNOSIS
Abstract

Renal cell carcinoma (RCC) comprises a heterogenous group of tumors. Traditionally, papillary RCC (pRCC) is associated with a favorable outcome compared to clear cell RCC (ccRCC), while other series report equivalent or worse prognosis. In this paper we comparatively evaluate outcome of pRCC versus ccRCC in two large multi-institutional databases (cohort study), including distribution of pRCC subtypes 1 and 2. Retrospective data of 1,943 surgically treated pRCC patients from 17 European/ North American centers between 1984–2015 were compared to 5,600 ccRCC patients from a database comprising 11 European/ North American centers (1984–2011). Median follow-up was 64.6 months. Differences between pRCC, subtypes, and ccRCC were compared with t-tests, Chi^2-tests, and exact Fisher tests. Cancer-specific mortality was analyzed with cumulative incidence curves and Cox cause-specific hazard models. The robustness of our results was examined with sensitivity analyses. We present that cancer-specific mortality rates and variables as stage, lymph node, and distant metastasis differ significantly between groups. Furthermore, we demonstrate that patients with non-metastatic pRCC had a significantly better cancer-specific mortality (HR 0.76, p = 0.007), when compared to ccRCC. Additionally, pRCC type 2 versus ccRCC exhibited no difference in cancer-specific mortality (HR 0.9, p = 0.722), whereas pRCC type 1 versus ccRCC displayed a risk of death reduced by 69% (p = 0.044). Taken together, outcome of pRCC versus ccRCC varies significantly in non-metastatic disease. Furthermore, pRCC type 2 exhibited no difference in cancer-specific mortality, whereas pRCC type 1 displayed a significantly reduced risk of death. Consequently, there is urgent need to respect histopathological entities and their subtypes, when assigning follow-up or targeted therapy to RCC patients. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

34. Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA subtype project).

Author

May, Matthias, Surcel, Cristian, Capitanio, Umberto, Dell'Oglio, Paolo, Klatte, Tobias, Shariat, Shahrokh, Ecke, Thorsten, Wolff, Ingmar, Vergho, Daniel, Wagener, Nina, Huck, Nina, Pahernik, Sascha, Zastrow, Stefan, Wirth, Manfred, Borgmann, Hendrik, Haferkamp, Axel, Musquera, Mireia, Krabbe, Laura M., Herrmann, Edwin, and Scavuzzo, Anna

Subjects
RENAL cell carcinoma, TUMOR classification, NEPHRONS, ONCOLOGIC surgery, CANCER-related mortality
Abstract

Objective:Studies on the prognostic reliability of the Union for International Cancer Control tumor, node, metastasis (TNM) staging system for renal cell carcinoma (RCC) predominantly focus on clear-cell RCC. Therefore, the aim of this study was to investigate whether the oncological prognosis of surgically treated papillary RCC (papRCC) patients is reliably given by the current TNM system, by analyzing the largest database reported to date. Materials and methods:Data on 2325 papRCC patients who underwent surgical treatment in 1984– 2015 were collated from 17 international centers (median follow-up 47 months). Tumor stage was adapted to the 7th edition of the TNM system. Multivariable, bootstrap-corrected Cox regression models were applied to assess the independent impact of the TNM system on cancer-specific mortality (CSM) and all-cause mortality (ACM). Results:The median age at diagnosis was 63 years (interquartile range 54–70 years) and 77% of patients were male. Nephron-sparing surgery was performed in 42%, and 82% were with symptom free at diagnosis. In 6.7% (n = 156), organ metastasis (stage M1) was present at the time of surgery. On multivariable analysis, the TNM system and Fuhrman grade had an independent impact on both CSM and ACM, while patient age affected ACM only. The discriminative ability of the pT classification was significant for both endpoints: 5 year CSM rates were 5%, 17%, 36% and 56% for stages pT1, pT2, pT3 and pT4, respectively (eachp < 0.001). The pT classification contributed significantly to the predictive accuracy of the CSM and ACM models by 6.3% and 2.5%, respectively (eachp < 0.001). Conclusions:The 2010 TNM staging system can be reliably applied to papRCC patients and allows certain prognostic discrimination. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

35. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

Author

Wagener, Nina, Macher-Göppinger, Stephan, Pritsch, Maria, Hüsing, Johannes, Hoppe-Seyler, Karin, Schirmacher, Peter, Pfitzenmaier, Jesco, Haferkamp, Axel, Hoppe-Seyler, Felix, Hohenfellner, Markus, Wagener, Nina, Macher-Göppinger, Stephan, Pritsch, Maria, Hüsing, Johannes, Hoppe-Seyler, Karin, Schirmacher, Peter, Pfitzenmaier, Jesco, Haferkamp, Axel, Hoppe-Seyler, Felix, and Hohenfellner, Markus

Abstract

Background: The enhancer of zeste homolog 2 (EZH2) gene exerts oncogene-like activities and its (over)expression has been linked to several human malignancies. Here, we studied a possible association between EZH2 expression and prognosis in patients with renal cell carcinoma (RCC). Methods: EZH2 protein expression in RCC specimens was analyzed by immunohistochemistry using a tissue microarray (TMA) containing RCC tumor tissue and corresponding normal tissue samples of 520 patients. For immunohistochemical assessment of EZH2 expression, nuclear staining quantity was evaluated using a semiquantitative score. The effect of EZH2 expression on cancer specific survival (CSS) was assessed by univariate and multivariate Cox regression analyses. Results: During follow-up, 147 patients (28%) had died of their disease, median follow-up of patients still alive was 6.0 years (range 0 - 16.1 years). EZH2 nuclear staining was present in tumor cores of 411 (79%) patients. A multivariate Cox regression analysis revealed that high nuclear EZH2 expression was an independent predictor of poor CSS (>25-50% vs. 0%: HR 2.72, p = 0.025) in patients suffering from non-metastatic RCC. Apart from high nuclear EZH2 expression, tumor stage and Fuhrman's grading emerged as significant prognostic markers. In metastatic disease, nuclear EZH2 expression and histopathological subtype were independent predictive parameters of poor CSS (EZH2: 1-5%: HR 2.63, p = 0.043, >5-25%: HR 3.35, p = 0.013, >25%-50%: HR 4.92, p = 0.003, all compared to 0%: HR 0.36, p = 0.025, respectively). Conclusions: This study defines EZH2 as a powerful independent unfavourable prognostic marker of CSS in patients with metastatic and non-metastatic RCC.

Published
2010

38. EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells

Author

Fussbroich, Bettina, primary, Wagener, Nina, additional, Macher-Goeppinger, Stephan, additional, Benner, Axel, additional, Fälth, Maria, additional, Sültmann, Holger, additional, Holzer, Angela, additional, Hoppe-Seyler, Karin, additional, and Hoppe-Seyler, Felix, additional

Published
2011
Full Text
View/download PDF

45. 947 THE PROBABILITY OF RENAL FUNCTION DECLINE AND NEW ONSET CHRONIC KIDNEY DISEASE IN URINARY DIVERSION – A RETROSPECTIVE COHORT STUDY COMPARING ILEAL CONDUIT AND ILEAL ORTHOTOPIC NEOBLADDER

Author

Hofner, Thomas, primary, Haferkamp, Axel, additional, Milakovic, Sdrjan, additional, Pfitzenmaier, Jesco, additional, Pahernik, Sascha, additional, Djakovic, Nenad, additional, Wagener, Nina, additional, Hadaschik, Boris, additional, and Hohenfellner, Markus, additional

Published
2010
Full Text
View/download PDF

49. Prognostic Factors Influencing Long-Term Survival of Patients Undergoing Nephron-Sparing Surgery for Nonmetastatic Renal-Cell Carcinoma (RCC) with Imperative Indications

Author

Haferkamp, Axel, primary, Kurosch, Martin, additional, Pritsch, Maria, additional, Hatiboglu, Gencay, additional, Macher-Goeppinger, Stephan, additional, Pfitzenmaier, Jesco, additional, Pahernik, Sascha, additional, Wagener, Nina, additional, and Hohenfellner, Markus, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results